LOGIN  |  REGISTER
Surmodics

List of Pharmaceutical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 807.43
-1.02 -0.13
1.63M
950.40M
US$ 767.380B
US$ 136.04
0.47 0.35
2.83M
4.45B
US$ 605.380B
US$ 146.97
-2.73 -1.82
8.33M
2.41B
US$ 354.200B
US$ 129.49
-1.60 -1.22
4.62M
2.53B
US$ 327.610B
US$ 157.06
-1.20 -0.76
3.18M
1.77B
US$ 278.000B
US$ 78.54
0.36 0.46
3.52M
3.10B
US$ 243.470B
US$ 100.53
-0.58 -0.57
1.15M
2.04B
US$ 205.080B
US$ 31.60
-0.19 -0.60
1.75M
6.38B
US$ 201.610B
US$ 305.84
-0.66 -0.22
2.42M
536.44M
US$ 164.060B
US$ 28.88
0.19 0.66
19.45M
5.67B
US$ 163.750B
US$ 48.54
-0.46 -0.94
1.42M
2.50B
US$ 121.350B
US$ 45.12
-0.03 -0.07
2.12M
2.04B
US$ 92.040B
US$ 41.24
-0.30 -0.72
16.77M
2.03B
US$ 83.720B
US$ 65.68
-0.49 -0.74
5.96M
1.25B
US$ 82.100B
US$ 170.07
-0.83 -0.49
1.84M
456.30M
US$ 77.600B
US$ 13.12
0.10 0.77
1.56M
3.14B
US$ 41.200B
US$ 217.81
-0.25 -0.11
761,778
145.60M
US$ 31.710B
US$ 7.54
0.06 0.80
1.39M
3.93B
US$ 29.620B
US$ 16.60
-0.16 -0.95
6.33M
1.13B
US$ 18.760B
US$ 9.99
0.13 1.32
410,355
1.79B
US$ 17.880B
US$ 16.03
0.08 0.50
10.38M
862.71M
US$ 13.830B
US$ 10.41
-0.12 -1.14
4.73M
1.19B
US$ 12.390B
US$ 69.53
-0.08 -0.11
256,590
166.53M
US$ 11.580B
US$ 33.27
-0.07 -0.21
767
330.82M
US$ 11.010B
US$ 54.82
0.17 0.31
1.72M
180.98M
US$ 9.920B
US$ 16.79
0.30 1.82
2.53M
494.18M
US$ 8.300B
US$ 20.99
-0.36 -1.69
990,699
257.17M
US$ 5.400B
US$ 7.20
0.09 1.27
1.14M
679.09M
US$ 4.890B
US$ 27.88
-0.24 -0.85
1.17M
136.32M
US$ 3.800B
US$ 18.73
0.01 0.05
91,849
170.73M
US$ 3.200B
US$ 37.20
0.07 0.19
530,717
76.70M
US$ 2.850B
US$ 17.37
0.65 3.89
116,096
135.14M
US$ 2.350B
US$ 6.36
0.01 0.16
2.01M
366.80M
US$ 2.330B
US$ 43.26
-0.09 -0.21
189,592
48.90M
US$ 2.120B
US$ 42.69
-0.06 -0.14
45,662
37.58M
US$ 1.600B
US$ 15.75
0.13 0.83
641,271
96.12M
US$ 1.510B
US$ 27.51
-0.26 -0.94
434,105
54.97M
US$ 1.510B
US$ 29.69
-0.63 -2.08
288,036
46.55M
US$ 1.380B
US$ 61.32
0.96 1.59
88,070
20.96M
US$ 1.290B
US$ 34.25
0.43 1.27
309,219
32.72M
US$ 1.120B
US$ 5.95
-0.11 -1.82
1.87M
158.96M
US$ 945.810M
US$ 12.51
0.06 0.48
241,731
62.61M
US$ 783.250M
US$ 13.13
0.14 1.08
298,609
57.67M
US$ 757.210M
C$ 6.00
0.04 0.67
72,823
106.76M
C$ 640.560M
US$ 17.89
0.39 2.23
248,086
35.38M
US$ 632.950M
US$ 19.80
0.12 0.61
126,850
29.52M
US$ 584.500M
US$ 18.55
0.09 0.49
80,739
20.34M
US$ 377.310M
US$ 2.63
-0.06 -2.23
369,194
132.57M
US$ 348.660M
US$ 7.84
0.22 2.89
654,162
42.29M
US$ 331.550M
US$ 2.76
0.15 5.75
6,456
112.82M
US$ 311.380M
US$ 5.30
0.08 1.53
6,887
57.48M
US$ 304.640M
US$ 4.76
-0.18 -3.64
1.39M
52.40M
US$ 249.420M
C$ 8.68
0.14 1.64
9,052
24.11M
C$ 209.270M
US$ 1.13
0.04 3.67
619,895
166.19M
US$ 187.790M
US$ 1.23
-0.04 -3.15
1.64M
146.38M
US$ 180.050M
US$ 0.17
0.0015 0.89
818,984
1.02B
US$ 173.910M
US$ 0.18
-0.0012 -0.68
4.07M
979.95M
US$ 172.370M
US$ 5.62
-0.07 -1.23
110,559
30.55M
US$ 171.690M
US$ 2.35
0.12 5.38
729,954
69.00M
US$ 162.150M
US$ 2.95
-0.04 -1.34
82,137
52.39M
US$ 154.550M
US$ 1.11
-0.02 -1.77
570,577
113.04M
US$ 125.470M
C$ 3.88
0.00 0.00
0
32.25M
C$ 125.130M
US$ 1.10
0.00 0.00
0
105.57M
US$ 116.130M
C$ 9.15
-0.04 -0.44
11,929
11.61M
C$ 106.230M
US$ 5.05
-0.28 -5.25
49,652
19.08M
US$ 96.350M
US$ 2.35
0.11 4.91
161,934
37.78M
US$ 88.780M
US$ 1.83
0.12 7.02
14,428
40.82M
US$ 74.700M
US$ 5.01
0.01 0.20
303
13.01M
US$ 65.180M
US$ 1.16
-0.10 -7.94
977,037
51.59M
US$ 59.840M
US$ 1.28
0.04 3.23
23,655
45.98M
US$ 58.850M
US$ 1.81
-0.005 -0.28
86,533
30.32M
US$ 54.880M
US$ 3.60
0.00 0.00
37,766
14.01M
US$ 50.440M
US$ 3.74
0.01 0.27
119,207
12.96M
US$ 48.470M
US$ 2.78
0.08 2.96
22,172
15.87M
US$ 44.120M
US$ 1.30
0.04 3.17
75,079
31.04M
US$ 40.350M
C$ 0.44
0.05 11.39
225,855
89.08M
C$ 39.200M
C$ 1.63
0.03 1.88
43,100
23.80M
C$ 38.790M
US$ 1.35
0.05 3.85
28,968
28.72M
US$ 38.770M
US$ 2.14
0.03 1.42
8,077
11.53M
US$ 24.670M
US$ 1.55
-0.02 -1.27
12,749
14.19M
US$ 21.990M
US$ 0.34
-0.0048 -1.39
81,235
55.22M
US$ 18.770M
US$ 1.03
-0.01 -0.96
7,715
16.99M
US$ 17.500M
US$ 1.07
-0.06 -5.30
24,753
14.00M
US$ 14.980M
US$ 4.77
-0.16 -3.25
69,153
2.86M
US$ 13.640M
US$ 0.89
0.005 0.57
70,378
14.78M
US$ 13.080M
US$ 9.25
0.15 1.65
3,081
1.28M
US$ 11.840M
US$ 0.70
0.02 2.21
40,976
16.85M
US$ 11.780M
C$ 1.09
0.04 3.81
400
10.25M
C$ 11.170M
C$ 0.10
0.00 0.00
74,105
98.63M
C$ 9.370M
US$ 2.99
0.05 1.59
1,483
3.06M
US$ 9.140M
US$ 1.38
0.17 14.05
287,924
6.41M
US$ 8.850M
US$ 2.40
-0.10 -4.00
9,132
3.65M
US$ 8.760M
C$ 0.43
-0.04 -8.51
5,661
20.37M
C$ 8.760M
US$ 5.65
-0.40 -6.61
11,788
1.41M
US$ 7.970M
US$ 0.41
-0.01 -2.72
14,422
16.89M
US$ 7.010M
C$ 0.05
0.00 0.00
15,000
132.70M
C$ 6.630M
US$ 1.05
-0.01 -0.94
26,300
5.09M
US$ 5.340M
US$ 0.29
-0.0003 -0.10
294,116
14.82M
US$ 4.370M
US$ 0.61
-0.0035 -0.57
56,106
6.88M
US$ 4.200M
US$ 0.43
-0.03 -7.10
47,103
8.48M
US$ 3.660M
US$ 0.20
0.0083 4.39
1.95M
15.61M
US$ 3.080M
US$ 1.80
0.00 0.00
0
1.61M
US$ 2.900M
C$ 0.02
-0.005 -20.00
53,000
132.63M
C$ 2.650M
US$ 0.37
-0.23 -37.74
9,040
6.86M
US$ 2.570M
C$ 0.02
-0.005 -25.00
2,200
164.72M
C$ 2.470M
US$ 0.23
0.00 0.00
0
10.09M
US$ 2.340M
US$ 0.70
-0.03 -3.87
59,972
2.47M
US$ 1.730M
US$ 0.87
-0.27 -23.68
544,086
1.76M
US$ 1.530M
US$ 1.07
0.01 0.94
122,360
913,167
US$ 977K
C$ 0.01
0.00 0.00
0
77.69M
C$ 777K
US$ 0.76
0.01 1.75
834,977
994,528
US$ 751K
C$ 0.005
0.00 0.00
256,500
98.09M
C$ 490K
US$ 0.0011
0.0005 83.33
100,000
64.47M
US$ 71K

Latest Pharmaceutical Stock News


Eli Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines

Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history Since 2020, the company has committed more than $18 billion to build, upgrade and acquire facilities in the U.S. and Europe INDIANAPOLIS, May 24, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing... Read more


European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

SHANGHAI, China & JERSEY CITY, N.J. / May 24, 2024 / Business Wire / Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an investigational Prolia® and Xgeva® (denosumab) biosimilar. Denosumab has been approved in various countries and regions under different trade names for a range of different indications such as for the treatment... Read more


HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL and online. Results will be presented from the registration Phase... Read more


Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities...

PRINCETON, N.J. / May 23, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2024 Hybrid Congress. Data from more than 130 company-sponsored studies, investigator-sponsored studies, and collaborations showcase results spanning approximately 25 cancer types and... Read more


Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

Poster highlights durable disease stabilization lasting beyond treatment completion Results suggest a unique, multimodal mechanism of action that differs from other cancer therapeutics Favorable tolerability sets stage for Part 3 (dose optimization) of Phase 1 trial, already underway MONTREAL, May 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the... Read more


Eli Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

INDIANAPOLIS, May 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a rearranged during transfection [RET] inhibitor), olomorasib (an investigational KRAS G12C inhibitor) and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking... Read more


Supernus Pharmaceuticals Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy

 SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced data from the planned interim analysis... Read more


Taro Pharmaceutical Shareholders Approve Merger with Sun Pharma

MUMBAI, India and NEW YORK, May 23, 2024 /CNW/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders (including a vote of the majority... Read more


AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)

Additional clinical and real-world data from the industry’s largest amyloidosis pipeline will advance understanding of underlying mechanisms of disease and unmet needs WILMINGTON, Del. / May 23, 2024 / Business Wire / AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the International Symposium on Amyloidosis (ISA), in Rochester,... Read more


Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

Consistent with short-term studies, KarXT was not associated with clinically meaningful changes in movement disorder scale scores and a low incidence rate of extrapyramidal symptoms was reported over long-term trials in adults with schizophrenia In-trial qualitative interviews found that the majority of participants treated with KarXT in the long-term EMERGENT-5 trial perceived improvements in positive, negative and cognitive symptoms of schizophrenia PRINCETON, N.J.... Read more




Gilead Sciences to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024

Key Findings from PBC, HDV, HCV, HBV and MASH/Fibrosis Studies Affirm Commitment to Drive Life-changing Science in Liver Disease  FOSTER CITY, Calif. / May 22, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy. Key findings from more than 25 abstracts will include: Interim results for two years from the ASSURE... Read more


Veru to Present at the Jefferies Global Healthcare Conference

MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present an update of Veru’s Phase 2b clinical program of enobosarm to augment fat loss... Read more


Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder

VANCOUVER, British Columbia, May 22, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, has entered a Letter of Intent (LOI) with ATMA Journey Centers (ATMA). ATMA is a pioneering Canadian firm focused on advancing innovative solutions in psychedelic-assisted therapy. The LOI outlines Optimi's... Read more


Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024

11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ  Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care  DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today it will present 11 posters, and one oral presentation, supporting the use of LUMRYZ as... Read more


Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases Felzartamab is an investigational anti-CD38 monoclonal antibody that, through its cell depletion approach, has demonstrated clinical proof of concept in rare immune-mediated indications, with plans to advance to Phase 3 Proposed acquisition builds on Biogen capabilities in immunology with plans to combine... Read more


AstraZeneca furthers ambition to transform outcomes in early lung cancer and ​redefine metastatic breast cancer treatment at ASCO 2024​

Back-to-back plenary presentations from LAURA and ADRIATIC Phase III trials reinforce the potential of TAGRISSO® (osimertinib) and IMFINZI® (durvalumab) in early lung cancer settings​ DESTINY-Breast06 data underscore potential of ENHERTU® (fam-trastuzumab deruxtecan-nxki) earlier in HR-positive, HER2-low breast cancer treatment, and in a broader population including HER2-ultralow WILMINGTON, Del. / May 22, 2024 / Business Wire / AstraZeneca advances its ambition... Read more


Amphastar Pharmaceuticals Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 22, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that the U.S. Food and Drug Administration ("FDA") has granted approval for the Company's Abbreviated New Drug Application ("ANDA") for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008. This product is for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention... Read more


Evotec Reports Q1 2024 Results and Provides Corporate Update

CHALLENGING Q1 WITH SOFTNESS MAINLY IN TRANSACTIONAL/DEVELOPMENT SHARED R&D BUSINESS AGAINST A STRONG COMPARABLE QUARTER STRONG START WITH JUST - EVOTEC BIOLOGICS IN Q1 2024 POSITIVE MOMENTUM IN SHARED R&D DISCOVERY CLOSED SALES POINT TO RECOVERY OF REVENUES TOWARDS END OF THE YEAR RESET FOR PROFITABLE GROWTH INITIATED, NEW REPORTING SEGMENTS INTRODUCED: SHARED R&D AND JUST - EVOTEC BIOLOGICS HAMBURG, GERMANY / ACCESSWIRE / May 22, 2024 / Evotec SE (Frankfurt... Read more


Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

Team composed of former FDA officials and key clinical and regulatory opinion leaders to help provide insight in preparation for collaboration with FDA NEW YORK, NY / ACCESSWIRE / May 21, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has formed an Advisory Committee to provide guidance as the company prepares for the potential Rx-to-OTC... Read more


MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

Ketamir-2, the Company's novel oral ketamine analog in development, aims to provide a safe and effective alternative for managing cancer pain and associated depression MIAMI, May 21, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced it is in advanced discussions with Memorial Sloan Kettering Cancer... Read more


More than one-half of patients with Crohn's disease treated with Eli Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure

Nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks; most of these patients were also in clinical remission INDIANAPOLIS, May 21, 2024 /PRNewswire/ -- In Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically significant and clinically meaningful improvements across multiple clinical and... Read more


DURECT Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial  CUPERTINO, Calif., May 21, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted... Read more


Zomedica to Present at the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

ANN ARBOR, MI / ACCESSWIRE / May 21, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024. Company Webcast The webcasted presentation will... Read more


Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

Updated Prescription Drug User Fee Act (PDUFA) goal date of December 29, 2024 PRINCETON, N.J. / May 21, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has reassigned the previously announced Prescription Drug User Fee Act (PDUFA) goal date of the Biologics License Application (BLA) for the subcutaneous formulation of Opdivo® (nivolumab) co-formulated with Halozyme’s proprietary recombinant human... Read more


Ironwood Pharmaceuticals Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF

New data highlight both stoma and colon-in-continuity (CIC) patients drove the positive primary endpoint with significant relative change from baseline in weekly parenteral support (PS) volume reduction at week 24  Additional secondary endpoints show significant increases in days off PS and clinical responder rates with apraglutide, including achieving enteral autonomy in both stoma and CIC patients  Data from largest GLP-2 Phase III study to date adds to body... Read more


Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA. “On behalf of the entire Avadel... Read more


Roche: FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting  Approximately 40% of people with HR-positive breast cancer have a PIK3CA mutation and often face poorer prognosis and resistance to endocrine treatment  This is the 29th Breakthrough Therapy Designation for Genentech’s oncology portfolio, a testament... Read more


BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates

Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025 Company will host a conference call and webcast today at 8:00 am ET GAITHERSBURG, Md. and NESS ZIONA, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that... Read more


Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%

NEW YORK, NY / ACCESSWIRE / May 21, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 first quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $7,541,046 for the quarter ended March 31, 2024, a 54% increase over gross revenues of... Read more


Teva Pharmaceutical and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® PARSIPPANY, N.J. & REYKJAVÍK, Iceland / May 20, 2024 / Business Wire / Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis,... Read more


Taro Pharmaceutical Provides Results for Year Ended March 31, 2024

HAWTHORNE, N.Y. / May 20, 2024 / Business Wire / Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2024. Quarter ended March 31, 2024 Highlights ─ compared to March 31, 2023 Net sales of $164.9 million increased $18.4 million, or 12.5%, principally due to new launches and gross-to-net (“GTN”) adjustments. Excluding the impact of GTN adjustments, sales... Read more


Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

Evolus dermal filler, Evolysse™ Lift, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months; Secondary endpoints for improvement in nasolabial fold severity showed statistically significant differences compared to Restylane-L at all measured timepoints for the entire 12-month study period Evolus dermal filler, Evolysse™ Smooth, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months;... Read more


Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog

Investigative studies are underway testing Ketamir-2 as the potential first at home ketamine analog treatment for PTSD, depression, and neuropathic pain, including cancer pain  MIAMI, May 20, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced that it has advanced new preclinical studies using Ketamir-2,... Read more


PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation

European Commission decides against adoption of negative opinion  Translarna authorization remains active in Europe  2024 revenue guidance paused  WARREN, N.J., May 20, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has decided not to adopt the CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna™ (ataluren) and has... Read more


ANI Pharmaceuticals Announces the Launch of Kionex® Suspension

BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use. Kionex® Suspension is the only commercially available therapeutically equivalent to the reference listed drug (RLD) SPS® Suspension for Oral or Rectal use. "The launch of Kionex® Suspension for Oral or Rectal use exemplifies our capability... Read more


Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate

NORTHVALE, NJ / ACCESSWIRE / May 20, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for generic Methotrexate Sodium 2.5 mg tablets. Methotrexate belongs to a class of drugs known as antimetabolites and will be sold under the Elite Laboratories,... Read more


AstraZeneca: New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease

Late-breaking results from the Phase IIa COURSE trial provide insight into TEZSPIRE’s impact on COPD exacerbations in patients with a broad range of eosinophil levels WILMINGTON, Del. / May 19, 2024 / Business Wire / The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking... Read more


Amgen: New Data Presented at ATS 2024 Show The Potential of Tezspire® to Help Patients Living with COPD

Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels THOUSAND OAKS, Calif., May 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil... Read more


Gilead Sciences: Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months Reduction in Patient-Reported Pruritus (Itching) was Rapid and Durable in Patients with Moderate to Severe Symptoms Positive Interim Results are Highly Consistent with Results from the Phase 3 RESPONSE Study of Seladelpar FOSTER CITY, Calif. / May 18, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD), following the... Read more


Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page... Read more


HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces:- (a) the retirement of Mr Simon To from the position as Chairman and Executive Director, after 23 years with the Company; and (b) the appointment of Dr Dan Eldar as the new Chairman. Dr Eldar has been a Non-executive Director of the Company since 2016. He has more than 30 years... Read more


Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

LAVAL, QC / ACCESSWIRE / May 17, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC). The data will be presented at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on Sunday, May 19, 2024, in Washington, D.C. "We are... Read more


AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®

AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD) Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYRIZI®) versus ustekinumab (STELARA®) in Crohn's disease include an economic analysis and oral presentation that assessed inflammation biomarkers  Additional presentations... Read more


HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association (“EHA”) Hybrid Congress,... Read more


Amgen: FDA Approves Imdelltra™ (Tarlatamab-dlle), The First And Only T-cell Engager Therapy For The Treatment of Extensive-stage Small Cell Lung Cancer

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif., May 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™... Read more


BioSyent Releases Financial Results for Q1 2024

MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights include:  (CAD) Q1 2024 % Change vs.Q1 2023 Trailing Twelve Months(TTM) March 31, 2024 % Change vs.TTMMarch 31, 2023 Canadian Pharma Sales 7,546,144 18 % 30,689,349 16 % International Pharma Sales - 0 % 1,047,747 789 % Total Company... Read more


Bayer: Elinzanetant significantly reduces frequency and severity of moderate to severe hot flashes associated with menopause

Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms (VMS; also known as hot flashes) over 12 weeks compared to placebo Consistent benefits were also seen across both studies in all three key secondary endpoints, with significant reduction in frequency of VMS at week 1, improvement in sleep disturbances and menopause-related quality... Read more


Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its abstract demonstrating enhanced gastroparesis care in women using nasal metoclopramide will be presented at the 2024 Digestive Disease Week Conference (DDW 2024) taking place May 18-21, 2024 in... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB